Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Psychiatric disorders – page 26

  • 548 clinical trials
  • 257 recruiting
  • 147 conditions
  • 26 countries

Conditions in this area

147 conditions with trials, the busiest first

Dementia Alzheimer's type87Major depression57Schizophrenia40Depression35Narcolepsy19Cognitive disorder18Bipolar disorder16Autism spectrum disorder15Insomnia15Post-traumatic stress disorder14Psychotic disorder14Drug use disorder13Alcohol use disorder12Attention deficit hyperactivity disorder9Dementia9Obstructive sleep apnoea syndrome9Brain injury8Irritable bowel syndrome8Phenylketonuria8Bipolar I disorder7Drug dependence7Hypersomnia7Lennox-Gastaut syndrome7Anorexia nervosa6+123

Clinical trials in Psychiatric disorders

548 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

548 clinical trials

A study to evaluate the effect of xanomeline tartrate and trospium chloride on cognitive impairment in adults with schizophrenia.

Not yet recruiting
InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:18–64 years
  • Substances:Trospium Chloride
  • Sponsor:European Group for Research in Schizophrenia Stichting

Autism spectrum disorder

Not yet recruiting

Testing the safety and effectiveness of stem cells from fat tissue in children with autism spectrum disorder and digestive problems

InvestigationalNo placebo
Countries:DenmarkDenmark
  • Participants:0–17 years
  • Sponsor:Cell to Cure ApS

Major depression

Not yet recruiting

A study of azetukalner compared to placebo for adults with moderate-to-severe major depressive disorder

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Azetukalner
  • Sponsor:Xenon Pharmaceuticals Inc.

Autism spectrum disorder

Not yet recruiting

Study of aldesleukin in children aged 4 to 6 years with autism spectrum disorder whose mothers had immune system activation during pregnancy

Investigational
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Aldesleukin
  • Sponsor:Assistance Publique Hopitaux De Paris

Cognitive disorder

Not yet recruiting

Study of Citicoline to Prevent Cognitive Decline After Delirium in Older Adults with Hip Fracture

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:65+ years
  • Sponsor:Universita Degli Studi Di Milano Bicocca

Depression

Not yet recruiting

Study of prucalopride and escitalopram combination to improve treatment response in patients with major depressive disorder

Registered drug
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Escitalopram
  • Sponsor:Centre Hospitalier Universitaire Grenoble Alpes

Alcohol abuse

Not yet recruiting

Study of cannabidiol compared to placebo to treat alcohol dependence in adults seeking treatment to achieve abstinence

Investigational
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:Cannabinol
  • Sponsor:Hospital Universitario 12 De Octubre

Study of cannabidiol to reduce self-injurious behavior in children and adolescents with severe neurodevelopmental disorders

Not yet recruiting
Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Cannabidiol
  • Sponsor:Assistance Publique Hopitaux De Paris

Dementia

Not yet recruiting

Study on Efgartigimod for Patients with Autoimmune Dementia

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Efgartigimod Alfa
  • Sponsor:Deutsches Zentrum Fuer Neurodegenerative Erkrankungen e.V.

Nervous system disorder+2

Not yet recruiting

Study on the Effects of Dexmedetomidine on Brain Fluid Flow and Activity in Patients with Neurodegenerative Diseases, Delirium, or Acute Neurological Conditions

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · Healthy volunteers
  • Substances:Dexmedetomidine
  • Sponsor:HUS-Yhtymae

Dementia Alzheimer's type

Not yet recruiting

Study on Thiethylperazine and Florbetaben (18F) for Early Alzheimer's Disease Patients

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Florbetaben (18F)
  • Sponsor:Immungenetics AG

Study on the Effects of AD04 and Placebo in Patients with Early Alzheimer's Disease

Not yet recruiting
Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Aluminium Hydroxide
  • Sponsor:Advantage Therapeutics GmbH

Substances studied in this area

The therapies tested most often in Psychiatric disorders trials.

Sodium Chloride25 clinical trialsTrospium Chloride18 clinical trialsXanomeline Tartrate17 clinical trialsCannabidiol15 clinical trialsDry Extract From Psilocybe Cubensis (15-25:1), Extraction Solvent: Methanol14 clinical trialsFlorquinitau (18F)14 clinical trialsOxytocin13 clinical trialsAripiprazole12 clinical trialsFlorbetaben (18F)12 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.